Self-Replicating mRNA Hits America, Cardiac Arrests Skyrocket, RFK Nomination Rocks the Bio-Pharmaceutical Complex

By Peter A. McCullough, MD, MPH

Please enjoy this quick-hitting update on Worldview Tube hosted by Brannon Howse. He led the program with news that Arcturus Therapeutics has received FDA clearance to proceed with a clinical trial for ARCT-2304, a self-amplifying mRNA vaccine candidate targeting H5N1 pandemic influenza. The Phase 1 clinical trial, funded by the National Institutes of Health (BARDA), will evaluate safety, reactogenicity, and immunogenicity in approximately 200 healthy adults in the United States. The vaccine utilizes Arcturus' STARR® self-amplifying mRNA technology and is part of the company's preparation efforts for potential future pandemics. Neither Arcturus nor BARDA has disclosed what will turn off self-replication or how this new technology will safely stop producing the potentially deadly H5N1 hemagglutinase Spike protein.

We covered the recent peer-reviewed report of skyrocketing cardiac arrests in Seattle after 98% of the population took the COVID-19 vaccine. Finally, we spent time on the tremendous impact the nomination of Robert F. Kennedy, Jr for Secretary of Health and Human Services is having on the Bio-Pharmaceutical Complex.

Please subscribe to Courageous Discourse as a paying ($5 monthly) or founder member so we can continue to bring you the truth.

Peter A. McCullough, MD, MPH

President, McCullough Foundation

www.mcculloughfnd.org

You can make a positive impact on these issues. Please donate to the McCullough Foundation www.mcculloughfnd.org

Hulscher, N., Cook, M. J., Stricker, R. B., McCullough, P. A. (2024). Excess Cardiopulmonary Arrest and Mortality after COVID-19 Vaccination in King County, Washington. J Emerg Med OA, 2(1), 01-11.